Brought to you by 
Vernalis teams up with Servier again in third cancer collaboration
27 Apr 2021
Executive Summary
Vernalis PLC and Servier SA are teaming up for the third time in another three-year collaboration that again uses Vernalis’ fragment and structure-based platform to discover drugs for an undisclosed oncology target. Vernalis will receive milestone payments as well as royalties on sales if a resulting product is commercialized.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vernalis teams up with Servier again in third cancer collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice